Bionano Genomics ($BNGO)
Great news: ir.bionanogenomics.com/single-news-re...
Hopelijk zorgen deze berichten binnenkort voor terug een ommezwaai en wat groene dagen.
Bionano Genomics Inc. BNGO, -6.96% shares rallied in the extended session Thursday after the genome analysis company’s quarterly revenue came in better than Wall Street expected. Bionano shares surged 10% after hours, following a 7% decline in the regular session to close at $4.41. The company reported a first-quarter loss of $9.9 million, compared with $10.5 million in the year-ago period. Revenue rose to $3.2 million from $1.1 million in the year-ago quarter. Analysts surveyed by FactSet had forecast revenue of $3 million. “2021 is off to a solid start for Bionano,” said Erik Holmlin, Bionano chief executive, in a statement. “In the first quarter, we sold a record number of flow cells, analyzed a record number of samples in our service lab, drove broad adoption of Saphyr instruments and ramped up the installation of Saphyr systems that weren’t yet operational because of 2020’s travel restrictions.” Bionano’s Saphyr system aids researchers in the development of gene-based drugs.
Bionano Genomics: Implied upside of 216%
If you want big-time risk versus reward, Wall Street would encourage you to take a closer look at genome analysis company Bionano Genomics (NASDAQ:BNGO). The 12-month consensus price target on Bionano is $13.92 a share, which projects up to 216% upside from the $4.41 it closed at on May 13.
The buzz surrounding this former penny stock is the development of its optical genome mapping (OGM) system, known as Saphyr. Late last year, Saphyr demonstrated superior genome detection sensitivity, relative to similar OGM technology from Pacific Biosciences. It was also considerably more cost-effective. A month later, Bionano released a study that identified three autism spectrum disorder risk genes. In short, Bionano's lead device may be able to uncover genetic abnormalities in various hard-to-treat diseases, which would make it easier for drug developers to target these genetic markers.
On the other hand, Bionano Genomics is probably years away from garnering an approval from the U.S. Food and Drug Administration for its device, and third-party licensing is unlikely to generate a lot of revenue. In the first quarter, it recognized just $3.17 million in sales, while losing close to $10 million.
The positive here is that Bionano ended March with $362 million in cash. That should be more than enough to sustain the company's operations for years to come. At this point, its valuation is a crapshoot that's completely dependent on Saphyr's long-term use case.
Het gaat de goede kant op met het aandeel. Gaan we weer snel richting ATH???
Helaas weinig animo op dit forum.
Maar dat gaat snel veranderen. Let maar op !!!
zie onderstaande 3 artikelen.
BNGO Stock: r/WallStreetBets Is Betting Big on a Short Squeeze for Bionano
3 Top Robinhood Stocks Wall Street Thinks Will Soar 25% or More
Bionano Stock Is Enticing on Strong Q1 Results and Saphyr’s Progress
Ik blijf gewoon zitten, heb hier veel vertrouwen in.
Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that Jason Priar has joined the company as its Chief Commercial Officer. Jason is a seasoned sales leader with experience scaling businesses from early stage to hundreds of millions in revenue. He has a deep understanding of how to penetrate clinical and research markets including genetic diseases and cancer. Been watching stocks like this
Zoals vrijdag al gepost: het gaat lekker en vandaag nog lekkerder :)
BNGO Stock: The Big News Lifting Bionano Genomics This Morning
Omzet ligt ook hoog vandaag.
nu al 262% tov gemiddelde.
Wordt het nog gekker? wat zal het hoogste punt vandaag worden?
Blijven we onder de 10 euro?
Het vertrouwen in bngo blijft torenhoog hier. Gaan mooie dingen aankomen komende jaren.
Direct naar Forum